Compare Novo Nordisk A/S (NVO) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Oxford Lane Capital Corp — how do they compare? Novo Nordisk A/S trades at $46.46 (market cap $207.85B), while Oxford Lane Capital Corp trades at $9.52 (market cap $909.61M). The key difference: Novo Nordisk A/S is far larger — about 228.5× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (25.76%). Which is the better fit depends on your goals.
| NVO | OXLC | |
|---|---|---|
Market Cap | $207.85B | $909.61M |
Sector | Health | Financials |
52-Week High | $63.98 | $18.75 |
52-Week Low | $35.29 | $8.15 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | 25.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
OXLC trades at $9.52, up 2.7% today, with a bullish technical signal from moving averages but mixed oscillators. The stock shows a low P/B of 0.88 and a high P/S of 92.8, with recent earnings misses in Q1 and Q2 2026. Dividend payments of $0.20 per share continue monthly, supported by positive net cash flow of $252.37M in 2025. Revenue declined sharply to -$580M in 2026 from $57M in 2025, raising sustainability concerns.
Outlook is cautious due to volatile earnings and high yield risks; analyst consensus is split with 50% buy ratings. Key risks include negative ROE/ROA and potential NAV decay. Opportunities exist if dividend stability persists amid market discounts, but investor vigilance on financial health is critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
